Skip to Main Content

Acer Therapeutics Inc. Securities Fraud Class Action

View Complaint
COMPANY         Acer Therapeutics Inc.
COURT United States District Court for the Southern District of New York
CASE NUMBER 19-cv-06137
JUDGE The Hon. Gregory Howard Woods III
CLASS PERIOD December 12, 2017 - June 24, 2019.
SECURITY TYPE  Common Stock

Case Background:

On July 1, 2019, the initial complaint in this securities class action was filed against Acer Therapeutics Inc. (“Acer” or the “Company”), and certain of Acer’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action brought on behalf of all persons and entities who purchased or otherwise acquired Acer securities from December 12, 2017 through June 24, 2019, (the “Class Period”) both dates inclusive.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, the complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (1) Acer lacked sufficient data to support filing EDSIVO’s NDA with the FDA for the treatment of vEDS; (2) the Ong Trial was an inadequate and ill-controlled clinical study by FDA standards, and was comprised of an insufficiently small group size to support EDSIVO’s NDA; (3) consequently, the FDA would likely reject EDSIVO’s NDA; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Current Status of Case:

On February 28, 2020, Lead Plaintiff filed a second amended complaint (the “Complaint”). Defendants filed a Motion to Dismiss the Complaint on May 1, 2020. On June 16, 2020, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.  Lead Plaintiff informed the Court of their intention to move to amend the Complaint.  On February 4, 2021, Lead Plaintiff filed a third amended complaint (the “Amended Complaint”).  On July 21, Lead Plaintiff filed a Motion for Approval of Settlement in the amount of $8,350,000.00.   Preliminary Approval of Settlement was granted on August 11, 2021.  On December 10, 2021, Plaintiffs filed a Motion for Final Approval of Settlement.  On January 7, 2022, the Court issued an Order of Final Approval of Settlement and entered Final Judgment. This action has concluded. 

The deadline to file a claim was December 8, 2021.  You may find additional information regarding the terms of the settlement and claim filing process at www.strategicclaims.net/acer or by calling Strategic Claims Services, at 866–274-4004. 

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Acer Therapeutics Inc. (Nasdaq: ACER) securities between December 12, 2017 and June 24, 2019, inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Acer Therapeutics Inc. prior to the Class Period?
Are you a current or former employee of Acer Therapeutics Inc.?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email